Patient Resource: The Hidden Connection - ILD and Rheumatic Disease Dr. Iazsmin Bauer Ventura, Chicago, talks about IL

Tweet Author

Tweet Content

Patient Resource: The Hidden Connection - ILD and Rheumatic Disease Dr. Iazsmin Bauer Ventura, Chicago, talks about ILD as a window to systemic disease as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/8rJm4O3hHU

18 September 2025

What you need to know about scleroderma-related lung fibrosis

What do you need to know about scleroderma-related lung fibrosis as a practicing rheumatologist? Here are takeaways from these guidelines and my practice.

RA-associated interstitial lung disease or bronchiectasis is assoc w/ increased risk of total and cause-specific mortali

Tweet Author

RheumNow

Tweet Content

RA-associated interstitial lung disease or bronchiectasis is assoc w/ increased risk of total and cause-specific mortality. retrospective cohort study using the Mass General Brigham Biobank 221 RA-LD cases (151 RA-ILD, 70 RA-BR). RA-LD higher mortality (34 vs 13/1000PY; HR

When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD When idiopathic inflammatory myopathies

Tweet Author

RheumNow

Tweet Content

When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD When idiopathic inflammatory myopathies (IIM) affect the lungs, the consequences can be serious. Interstitial lung disease (ILD) is not only common in IIM, but also one of the leading causes of death, https://t.co/qRoTr3r84x

STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia Deane et al has published the results of the STOP-RA trial, demo

Tweet Author

RheumNow

Tweet Content

STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia Deane et al has published the results of the STOP-RA trial, demonstrating that 12 months of hydroxychloroquine (HCQ) did not prevent the development of clinical RA at 36 months. https://t.co/HLLhwgcVrS https://t.co/MKpeXhVdoe

Links

https://buff.ly/em7n8nc

Retrospective study of 201 IPAF (Interstitial pneumonia w/ autoimmune feat.) pts w/ F/U 5.6 yrs. ANA+ 80%, RF+ 25%, CCP+

Tweet Author

RheumNow

Tweet Content

Retrospective study of 201 IPAF (Interstitial pneumonia w/ autoimmune feat.) pts w/ F/U 5.6 yrs. ANA+ 80%, RF+ 25%, CCP+ 14%, 88% Rx w/ IS or antifibrotics. 24% died, 7.5% transplant. Comorbidies were common; mean CCI 3.2; IPAF mortality worsened by

Commercial claims analysis of 8855 adults w/ axSpA and/or PsA, 1771 who had joint replacements. JAK inhibitor use did no

Tweet Author

RheumNow

Tweet Content

Commercial claims analysis of 8855 adults w/ axSpA and/or PsA, 1771 who had joint replacements. JAK inhibitor use did not significantly reduce joint replacement (OR 0.67; 0.41–1.08), BUT TNFi, Non-TNFi biologics & DMARD users had signif fewer surgeries (OR ~0.65) vs NSAID users https://t.co/vnBnFcPxGw

🆕 ILD (Part II): advanced insights 🫁 Multidisciplinary management 💊 Treatment strategies 📊 Prognosis &

Tweet Author

RheumNow

Tweet Content

🆕 ILD (Part II): advanced insights 🫁 Multidisciplinary management 💊 Treatment strategies 📊 Prognosis & monitoring 🧑⚕️ What rheums should know next ⬇️ Download & learn more: https://t.co/dmhULfqiMj Created by @MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/ivvDjxkCvt

Links

ILD: Diagnosis and Subtypes (Part Two) | RheumNow https://buff.ly/DmxD6ug

17 September 2025

GLP-1 drugs cost-effective for knee osteoarthritis and obesity

A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for people with knee osteoarthritis and obesity, with tirzepatide providing greater health benefits at lower cost compared to semaglutide.

SUA levels & adverse health outcomes? Australian ASPREE trial of 11,878 older participants had baseline SUA measurem

Tweet Author

RheumNow

Tweet Content

SUA levels & adverse health outcomes? Australian ASPREE trial of 11,878 older participants had baseline SUA measurements. SUA levels had NO ASSOC. w/ all-cause mortality, disability-free survival, CV Dz, MACE, cancer mortality, cognitive decline, or dementia. In females, low SUA https://t.co/VY6NJsetW9

Topics

Patient Resource: The Hidden Connection - ILD and Rheumatic Disease Dr. Iazsmin Bauer Ventura, Chicago, talks about IL

RA-associated interstitial lung disease or bronchiectasis is assoc w/ increased risk of total and cause-specific mortali

When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD When idiopathic inflammatory myopathies

STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia Deane et al has published the results of the STOP-RA trial, demo

Retrospective study of 201 IPAF (Interstitial pneumonia w/ autoimmune feat.) pts w/ F/U 5.6 yrs. ANA+ 80%, RF+ 25%, CCP+

Commercial claims analysis of 8855 adults w/ axSpA and/or PsA, 1771 who had joint replacements. JAK inhibitor use did no

🆕 ILD (Part II): advanced insights 🫁 Multidisciplinary management 💊 Treatment strategies 📊 Prognosis &

SUA levels & adverse health outcomes? Australian ASPREE trial of 11,878 older participants had baseline SUA measurem

Do you get our email newsletter?